Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 786359, 2 pages
http://dx.doi.org/10.1155/2008/786359
Editorial

Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities

1Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
2Department of Biology, Metabolex, Inc., 3876 Bay Center Place, CA 94545, USA

Received 31 December 2008; Accepted 31 December 2008

Copyright © 2008 Jane A. Pinaire et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at PubMed
  2. A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels, “Safety issues and prospects for future generations of PPAR modulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1065–1081, 2007. View at Publisher · View at Google Scholar · View at PubMed
  3. B. G. Shearer and A. N. Billin, “The next generation of PPAR drugs: do we have the tools to find them?,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1082–1093, 2007. View at Publisher · View at Google Scholar · View at PubMed
  4. C. Fiévet, J.-C. Fruchart, and B. Staels, “PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome,” Current Opinion in Pharmacology, vol. 6, no. 6, pp. 606–614, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. C. R. Waites, M. A. Dominick, T. P. Sanderson, and B. E. Schilling, “Nonclinical safety evaluation of muraglitazar, a novel PPARα/γ agonist,” Toxicological Sciences, vol. 100, no. 1, pp. 248–258, 2007. View at Publisher · View at Google Scholar · View at PubMed
  6. P. Balakumar, M. Rose, S. S. Ganti, P. Krishan, and M. Singh, “PPAR dual agonists: are they opening Pandora's Box?,” Pharmacological Research, vol. 56, no. 2, pp. 91–98, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Publisher · View at Google Scholar · View at PubMed